Reason #3: Another Asset With Phase 3 Data Soon
Ocugen provided one more reminder for investors toward the end of the release. The company said:
Ocugen is also continuing enrollment in its Phase 3 study for OCU300 for ocular graft versus host disease. Ocugen anticipates receiving topline results for the Phase 3 study in the second half of 2020.
This is very important. At the end of the day, this pivotal clinical trial could be the trial that pushes the company toward a New Drug Application with the FDA. As such, it, alone, will likely lead to multiple catalysts. Keep your eyes peeled for:
- Interim data readouts.
- Topline data readout.
- Discussions with the FDA.
- New Drug Application.
All four of these catalysts are likely ahead with regard to OCU300.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!